Krystal Biotech Hits New 52-Week High of $212.98, Showcasing Strong Growth

Krystal Biotech, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 212.98 on November 4, 2025. This achievement underscores the company's robust performance over the past year, with a notable increase of 14.95% compared to the S&P 500's performance of 19.89%.
The company boasts a market capitalization of USD 4,203 million and maintains a price-to-earnings (P/E) ratio of 27.00. With a return on equity of 15.20% and a price-to-book ratio of 4.04, Krystal Biotech demonstrates solid financial health. The firm has reported a remarkable growth in net profit of 146.23% as of June 25, and has consistently delivered positive results for the last seven consecutive quarters.

Additionally, the company has achieved its highest operating cash flow at USD 195.4 million, while its net profit for the half-year reached USD 74.07 million, growing at 80.08%. With high institutional holdings at 100%, Krystal Biotech is well-positioned within its industry, reflecting strong confidence in its fundamentals.